Candel Therapeutics News and Activities

View the org chart displaying its 28 main executives

Most searched biographies at Candel Therapeutics

• Paul-Peter Tak, Director, President and Chief Executive Officer
• Chris Martell, Director
• Edward Benz, Director

Popular executive movements at Candel Therapeutics

• Allison Nylen, who was Director, Finance, is promoted to Corporate Controller  (posted on January 14 2026).
• Kristin Kennedy, Corporate Controller, has left the company  (posted on January 14 2026).
• Alex Cardoso, who was Senior Director, Manufacturing, is promoted to Vice President, Manufacturing  (posted on September 29 2025).

Create your alert
to follow the executive moves at Candel Therapeutics.

Candel Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Candel Therapeutics

• Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer | Candel Therapeutics, Inc
• Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Candel Therapeutics, Inc
• Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Candel Therapeutics, Inc
• Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston | Candel Therapeutics, Inc
• Candel Therapeutics Announces Proposed $100 Million Public Offering | Candel Therapeutics, Inc
• View more press releases Close

Social media about Candel Therapeutics

• Candel Therapeutics on Wikipedia, Google News & Yahoo Finance
• Candel Therapeutics on LinkedIn, X (Twitter) & YouTube